China FDA Likely To Change Pricing Mechanism Of Branded Generics
This article was originally published in PharmAsia News
China FDA recently announced that assessment of 75 generic drugs has been completed, and the agency sees no reason to have separate pricing policies for branded generics versus generic.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.
GSK commits to investing behind OTC and oral health brands in India after offloading nutrition assets to Unilever.